News & Updates
Showing Pharmacy articles
Showing
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
04 Dec 2022
First-line serplulimab + chemo ups survival in extensive-stage SCLC
The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.
First-line serplulimab + chemo ups survival in extensive-stage SCLC
02 Dec 2022
ADHD medication use carries no excess risk of cardiovascular diseases
Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.
ADHD medication use carries no excess risk of cardiovascular diseases
02 Dec 2022
SG, HK docs delay prescribing clozapine for treatment-resistant schizophrenia
Clinicians in Singapore and Hong Kong appear to delay the initiation of clozapine for treatment-resistant schizophrenia (TRS) despite familiarity with treatment guidelines, as reported in a study.
SG, HK docs delay prescribing clozapine for treatment-resistant schizophrenia
02 Dec 2022
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
02 Dec 2022
3-month rivaroxaban use safe, effective in isolated DVT
Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.
3-month rivaroxaban use safe, effective in isolated DVT
01 Dec 2022
Intensive antihypertensive therapy vital in kids with arterial hypertension after CoA repair
Close blood pressure (BP) monitoring and more intensive and combined antihypertensive therapy are needed when there is a high prevalence of uncontrolled arterial hypertension (AH) despite the successful coarctation of the aorta (CoA) correction and use of relatively low doses of antihypertensive drugs, suggests a recent study.
